Introduction: Triple negative breast cancer is defined as a tumor subtype characterized by the lack of expression of hormone receptors for estrogen and progesterone, and human epidermal growth factor receptor 2 (HER2)are considered to be biologically aggressive with higher rates of distant and visceral metastasis. The objective of the study was to describe the outcomes of patients with triple-negative breast cancer according to treatment and stage at the time of diagnosis in the population attended Mederi Hospital. Methodology: Descriptive study of a cohort of women with breast cancer with triple negative subtype attended in the University Hospital Mayor -Mederi between 2014-2018. Results: 28 patients were studied. The proportion of cases for the study population was 7.4% of all cases of breast cancer, the average age was 69 years. 71% were multi-pregnancy and 85% menopausal. 71% had infiltrating tumors and the most frequent clinical stage was IIIB; the outcome of mortality was 7.1% (two cases), and 71% of the patients had a disease-free period as an outcome. Conclusion: Patients diagnosed with triple negative breast cancer from the HUM Mastology Service presented pathological clinical characteristics similar to those reported in the literature, the risk of progression and relapse is given by the type of tumor and tumor infiltration, as well as the complete pathological response
publication date
February 18, 2021 4:37 PM
Research
keywords
Analysis of clinical outcomes according to treatment and stage of diagnosis
Characterization of adjuvant and Neoadjuvant treatments in the treatment of breast cancer
